% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Angelova:292156,
      author       = {A. L. Angelova$^*$ and M. Barf$^*$ and A. Just$^*$ and B.
                      Leuchs$^*$ and J. Rommelaere$^*$ and G. Ungerechts$^*$},
      title        = {{H}-1 {P}arvovirus-{I}nduced {O}ncolysis and {T}umor
                      {M}icroenvironment {I}mmune {M}odulation in a {N}ovel
                      {H}eterotypic {S}pheroid {M}odel of {C}utaneous {T}-{C}ell
                      {L}ymphoma.},
      journal      = {Cancers},
      volume       = {16},
      number       = {15},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01644},
      pages        = {2711},
      year         = {2024},
      note         = {#EA:D490#LA:D490#},
      abstract     = {The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus
                      known for its anticancer properties in laboratory models of
                      various human tumors, including non-Hodgkin lymphomas (NHL)
                      of B-cell origin. However, H-1PV therapeutic potential
                      against hematological malignancies of T-cell origin remains
                      underexplored. The aim of the present study was to conduct a
                      pilot preclinical investigation of H-1PV-mediated oncolytic
                      effects in cutaneous T-cell lymphoma (CTCL), a type of NHL
                      that is urgently calling for innovative therapies. We
                      demonstrated H-1PV productive infection and induction of
                      oncolysis in both classically grown CTCL suspension cultures
                      and in a novel, in vivo-relevant, heterotypic spheroid
                      model, but not in healthy donor controls, including
                      peripheral blood mononuclear cells (PBMCs). H-1PV-mediated
                      oncolysis of CTCL cells was not prevented by Bcl-2
                      overexpression and was accompanied by increased
                      extracellular ATP release. In CTCL spheroid co-cultures with
                      PBMCs, increased spheroid infiltration with immune cells was
                      detected upon co-culture treatment with the virus. In
                      conclusion, our preclinical data show that H-1PV may hold
                      significant potential as an ingenious viroimmunotherapeutic
                      drug candidate against CTCL.},
      keywords     = {cutaneous T-cell lymphoma (CTCL) (Other) / heterotypic CTCL
                      spheroid (Other) / oncolytic H-1 parvovirus (Other) /
                      virotherapy (Other)},
      cin          = {D490 / D430 / Z999},
      ddc          = {610},
      cid          = {I:(DE-He78)D490-20160331 / I:(DE-He78)D430-20160331 /
                      I:(DE-He78)Z999-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39123440},
      pmc          = {pmc:PMC11311363},
      doi          = {10.3390/cancers16152711},
      url          = {https://inrepo02.dkfz.de/record/292156},
}